A Real-world Study of Albumin-bound Paclitaxel in the Treatment of Pancreatic Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Pancreatic cancer progresses rapidly and has a higher death rate. Albumin-bound paclitaxel is a new generation of paclitaxel . Albumin-bound paclitaxel is recommended as a class 1A evidence treating patients with pancreatic cancer.The purpose of this study was to further observe and evaluate the clinical efficacy and safety of albumin-bound paclitaxel in the treatment of non-operative locally advanced or metastatic pancreatic cancer and to explore the prognostic factors .
Condition or disease
This is a prospective, single-arm, observational study. After the subjects meet the inclusive and exclusive criteria, then they will receive albumin-bound paclitaxel treatment. The researchers can choose the treatment based on albumin-bound paclitaxel and choose dosage according to the patient's condition.
the date from enrollment to the first occurrence of disease progression or death from any cause, whichever occurs first.
Biospecimen Retention: Samples With DNA
Patients enrolled in the study underwent whole-gene sequencing based on their willingness to take tumor tissue samples and blood samples.All samples need tissue samples and peripheral blood as control. Tissue samples can be wax blocks, fresh surgical tissues,tissues through puncture biopsy, laparoscopic biopsy and other biopsy. Sampling should be conducted within 1 week before enrollment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age: 18 -80, male or female;
Non-operative patients with locally advanced or metastatic pancreatic cancer diagnosed by pathology or histology (except islet cell carcinoma);
The patient has not received standard systematic treatment in the past, and the metastatic site has not received any local treatment, including radiotherapy, chemotherapy, surgical treatment, etc.;
At least one measurable lesion (CT scan length of tumor lesion is greater than 10 mm, CT scan short diameter of lymph node lesion is greater than 15 mm, scanning layer thickness is not greater than 5 mm);
The subjects volunteered to participate in this study and signed the informed consent form, with good compliance to follow-up.
Pregnant or lactating women;
Patients allergy to albumin-bound paclitaxel or its excipients
Patients with albumin-bound paclitaxel contraindication;
Doctors consider those who are not suitable for this study.